Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
  • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
  • C07C69/708—Ethers
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
  • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
  • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
  • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
  • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
  • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
  • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
  • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
  • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
  • C07C235/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
  • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
  • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
  • C07C59/40—Unsaturated compounds
  • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
  • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
  • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
  • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
  • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
  • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
  • C07C69/708—Ethers
  • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Definitions

• the present invention relates to organic compounds, their preparation and their use as pharmaceuticals.
• the present invention provides compounds of formula (I)
• Q is selected from -C(O)OR 6 , and -C(O)NR 7 R 8 ;
• R 1 is selected from OH, R 1a S-, R 1a O- and R 13 NR 9 -, wherein R 1a is ° wherein R 1b and R 1c are, independently, H, C ⁇ C 8 -alkyl, or together with the carbon atom to which they are attached form a divalent C 3 -C 8 -cycloaliphatic group;
• R 2 and R 3 are, independently, H, Ci-C ⁇ -alkyl, or together with the carbon atom to which they are attached form a divalent C 3 -C 8 -cycloaliphatic group;
• R 4 and R 5 are, independently, halogen, Ci-C 8 -alkyl, Ci-C 8 -haloalkyl, a C 3 -Ci 5 -carbocyclic group, nitro, cyano, Ci-C 8 -alkylsulfinyl, Ci-C 8 -alkylsulfonyl, CrC ⁇ -haloalkylsulfonyl, Ci-C 8 -alkoxycarbonyl, Ci-C 8 -alkoxy, Ci-Cs-haloalkoxy, carboxy, carboxy-C T Cs-alkyl, amino, Ci-C 8 -alkylamino, SO 2 NH 2 , (CrC ⁇ -alkylaminoJsulfonyl, di(Ci-C ⁇ -alkyl)aminosulfonyl, aminocarbonyl, C ⁇ Cs-alkylaminocarbonyl, di(C 1 -C 8 -alkyl)aminocarbon
• R 6 is selected from H, C r C 8 -alkyl, C 3 -C 5 -cycloalkyl, Ci-Cs-alkyKC ⁇ -Cis-aromatic carbocyclic group) and C 6 -C 15 -aromatic carbocyclic group;
• R 7 is H or d-C ⁇ -alkyl;
• R 8 is C 3 -C 15 -cycloalkyl;
• R 9 and R 10 are, independently selected from H, Ci-C 8 -alkyl, C 3 -C 15 -cycloalkyl,
• X is -CH 2 -, -CHCd-C ⁇ -alkyl)-, -CO-, -CH(OH)-, -CHfOd-C ⁇ -alkyl)-, -C(halogen) 2 -, -O-, -S-, -SO- or -SO 2 -;
• Y is -0-, -S-, -CH 2 - or -NR 11 (d-C 8 -alkyl)-;
• R 11 is selected from H, d-C ⁇ -alkyl, C 3 -C 15 -cycloalkyl, d-Ca-alkyKC ⁇ -ds-aromatic carbocyclic group), and C 6 -C 15 -aromatic carbocyclic group; m and n are each, independently, an integer selected from 0-3; v is an integer selected from 1-3; and w is an integer selected from 0-3, with the proviso that said compound of formula (I) is not [2-(2-carboxymethoxy-5-chloro- benzyl)-4-chloro-phenoxy]-acetic acid, [2-(2-carboxymethoxy-5-methyl-benzyl)-4-methyl- phenoxy]-acetic acid, 2- ⁇ 2-[2-(1 -carboxy-1 -methyl-ethoxy)-5-chloro-benzyl]-4-chloro- phenoxy ⁇ -2-methyl-propionic acid, 2- ⁇ 2-[(1-carboxyeth
• m or n 2
• the two moieties R 4 or two moieties R 5 may be the same or different.
• m or n 3
• two or all of the three moieties R 4 or the three moieties R 5 may be the same or all three may be different.
• Q is selected from -C(O)OR 6 , where R 6 is suitably H or C 1 - C 8 -alkyl, such as methyl, ethyl, isopropyl, and isobutyl.
• Q is selected from -C(O)NR 7 R 8 , where R 7 is suitably H and R 8 is suitably C 3 -C 15 cycloalkyl, such as a cyclopropyl ring.
• R 1 is selected from OH and , where R 1b and R 1c are independently selected from H and Ci-C 8 -alkyl.
• R 2 and R 3 are suitably H.
• R 4 and R 5 are selected from H, halogen, nitro, and C 1 -C 8 - alkyl.
• 1 X is suitably -CH 2 -, -CHfd-Cs-alkyl)-, -CO-, -CH(OH)-, - CH(OC 1 -C 8 -alkyl)-, -C(halogen) 2 -, -O-, -S-, -SO- or -SO 2 -.
• Y is -0-, -S-, -CH 2 - or -NR 11 (C 1 -C 8 -alkyl)-, where
• R 11 is selected from H, d-C ⁇ -alkyl, C 3 -C 15 -cycloalkyl, d-C ⁇ -alkyKCe-ds-aromatic carbocyclic group), and C 6 -C 15 -aromatic carbocyclic group.
• m and n are each, suitably 1.
• v is an integer selected from 1-3.
• w is an integer selected from 1.
• Another embodiment of the present invention provides compounds in free or pharmaceutically acceptable salt form, wherein the compound is of formula (Ia) wherein
• Q is selected from -C(O)OR 6 , and -C(O)NR 7 R 8 ;
• R 2 and R 3 are H;
• R 6 is H or C ⁇ Ce-alkyl, such as methyl, ethyl, isopropyl, and isobutyl;
• R 7 is H;
• R 8 is C 3 -C 15 cycloalkyl, such as a cyclopropyl ring
• R 12 and R 13 are, independently, H, halogen, nitro, or d-C 8 -alkylsulfonyl, such as - SO 2 CH 3 ;
• X is -CH 2 -, S, -SO- or -SO 2 -, preferably -CH 2 -; and w is 1.
• the present invention provides for the use of a compound of formula (I) in any of the aforementioned embodiments, in free or pharmaceutically acceptable salt form, for the manufacture of a medicament for the treatment of an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease.
• Halogen or halo may be fluorine, chlorine, bromine or iodine; preferably it is bromine or chlorine or fluorine.
• Ci-C 8 -Alkyl denotes straight-chain or branched d-C 8 -alkyl, which may be, e.g., methyl, ethyl, n-propyl, isopropyl, ⁇ -butyl, isobutyl, sec-butyl, te/t-butyl, straight- or branched- pentyl, straight- or branched-hexyl, straight- or branched-heptyl or straight- or branched-octyl.
• d-C 8 -alkyl is d-C 4 -alkyl.
• C 3 -Ci 5 -Carbocyclic group denotes a carbocyclic group having 3- to 15-ring carbon atoms, e.g., a monocyclic group, either cycloaliphatic, such as a C 3 -C 8 -cycloalkyl, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; or aromatic, such as phenyl; or a bicyclic group, such as bicyclooctyl, bicyclononyl including indanyl and indenyl, and bicyclodecyl including naphthyl.
• cycloaliphatic such as a C 3 -C 8 -cycloalkyl, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohept
• the C 3 -C 15 -carbocyclic group is a C 3 -C 10 -carbocyclic group, e.g., phenyl or naphthyl.
• the C 3 -Ci 5 -carbocyclic group can be substituted with 1-3 substituents or unsubstituted.
• Preferred substituents include halo, cyano, amino, nitro, carboxy, Ci-C 8 -alkyl, d-C 8 -haloalkyl, d-Cs-alkoxy, Ci-C 8 -alkylcarbonyl, d-C 8 -alkoxycarbonyl, d-C 8 -haloalkoxy, carboxy-d-C 8 - alkyl, d-C 8 -alkylamino, di(Ci-C 8 -alkylamino), d-C 8 -alkylsulfonyl, -SO 2 NH 2 , (d-C ⁇ -alkylaminoJsulfonyl, diCd-Ca-alky ⁇ aminosulfonyl, aminocarbonyl, d-C 8 -alkylaminocarbonyl and di(d-C 8 -alkyl)aminocarbonyl, a C 3 -C 10 -carbocyclic
• C 6 -C 15 -Aromatic carbocyclic group denotes a divalent aromatic group having 6- to 15-ring carbon atoms, e.g., phenylene, naphthylene or anthrylene.
• the C 6 -C 15 -aromatic group can be substituted with 1-3 substituents or can be unsubstituted.
• Preferred substituents include halo, cyano, amino, nitro, carboxy, d-C 8 -alkyl, !IaIo-C 1 -C 8 - alkyl, d-C 8 -alkoxy, d-C 8 -alkylcarbonyl, d-C 8 -alkoxycarbonyl, d-C 8 -haloalkoxy, carboxy- d-C 8 -alkyl, d-C 8 -alkylamino, di(d-C 8 -alkylamino), C r C 8 -alkylsulfonyl, -SO 2 NH 2 , (d-C 8 -alkylamino)sulfonyl, di(Ci-C 8 -alkyl)aminosulfonyl, aminocarbonyl, d-C 8 -alkylaminocarbonyl and diCd-Cs-alkylJaminocarbonyl, a C
• “Divalent C 3 -C 8 -cycloaliphatic” denotes cycloalkylene having 3- to 8-ring carbon atoms, e.g., a monocyclic group, such as a cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene or cyclooctylene, any of which can be substituted by one or more, usually one or two, d-C 4 -alkyl groups; or a bicyclic group, such as bicycloheptylene or bicyclooctylene.
• C 3 -C 8 -cycloalkylene is C 3 -C 5 -cycloalkylene, e.g., cyclopropylene, cyclobutylene or cyclopentylene.
• C 1 -C 8 -AIkOXy denotes straight-chain or branched d-C 8 -alkoxy which may be, e.g., methoxy, ethoxy, n-propoxy, isopropoxy, /7-butoxy, isobutoxy, sec-butoxy, te/t-butoxy, straight- or branched-pentoxy, straight- or branched-hexyloxy, straight- or branched- heptyloxy or straight- or branched-octyloxy.
• d-C 8 -alkoxy is d-C 4 -alkoxy.
• Ci-C 8 -Haloalkyl and Ci-C 8 -alkoxy denote Ci-C 8 -alkyl and Ci-C 8 -alkoxy, as hereinbefore defined, substituted by one or more halogen atoms, preferably one, two or three halogen atoms, preferably fluorine, bromine or chlorine atoms.
• Ci-C 8 -haloalkyl is Ci-C 4 -alkyl substituted by one, two or three fluorine, bromine or chlorine atoms.
• d-C 8 -haloalkoxy is d-C 4 -alkoxy substituted by one, two or three fluorine, bromine or chlorine atoms.
• d-Cs-Alkylsulfonyl denotes Ci-C ⁇ -alkyI, as hereinbefore defined, linked to -SO 2 -.
• d-C 8 -alkylsulfonyl is d-C 4 -alkylsulfonyl, especially methylsulfonyl.
• amino-d-Ce-alkyl and “amino-d-C 8 -alkoxy” denote amino attached by a nitrogen atom to d-Cs-alkyl, e.g., NH 2 -(C 1 -C 8 )-, or to C r C 8 -alkoxy, e.g., NH 2 -(C 1 -Cs)-O-, respectively, as hereinbefore defined.
• amino-d-Cs-alkyl and amino-CrC 8 -alkoxy are, respectively, amino-d-C 4 -alkyl and amino-C 1 -C 4 -alkoxy.
• amino-(hydroxy)-C 1 -C 8 -alkyl denotes amino attached by a nitrogen atom to d-C 8 -alkyl and hydroxy attached by an oxygen atom to the same Ci-C 8 -alkyl.
• amino-(hydroxy)-C 1 -C 8 -alkyl is amino-(hydroxy)-C 2 -C 4 -alkyl.
• Carboxy-d-C ⁇ -alkyl and “carboxy-CrCs-alkoxy” denote carboxy attached by a carbon atom to d-C 8 -alkyl or d-C 8 -alkoxy, respectively, as hereinbefore defined.
• carboxy-d-C ⁇ -alkyl and carboxy-C r C 8 -alkoxy are, respectively, carboxy-d-C 4 - alkyl and carboxy-d-C 4 -alkoxy.
• CrC ⁇ -Alkylcarbonyl denotes d-C 8 -alkyl, C r C 8 -alkoxy or d-C 8 -haloalkyl, respectively, as hereinbefore defined, attached by a carbon atom to a carbonyl group.
• d-Cs-Alkoxycarbonyl denotes d-C ⁇ -alkoxy, as hereinbefore defined, wherein the oxygen of the alkoxy group is attached to the carbonyl carbon.
• CrC ⁇ -alkylcarbonyl, d-C 8 -alkoxycarbonyl and d-C 8 -haloalkylcarbonyl are, respectively, d-d-alkylcarbonyl, d-C 4 -alkoxycarbonyl and d-d-haloalkylcarbonyl.
• Ci-C 8 -Alkylamino and "di(d-C 8 -alkyl)amino" denote Ci-C 8 -alkyl, as hereinbefore defined, attached by a carbon atom to an amino group.
• the d-C ⁇ -alkyl groups in di(C 1 -C 8 - alkyl)amino may be the same or different.
• d-C 8 -alkylamino and di(d-C 8 - alkyl)amino are, respectively, d-C 4 -alkylamino and di(d-C 4 -alkyl)amino.
• d-C ⁇ -Alkylaminocarbonyl and "di(d-C 8 -alkyl)aminocarbonyl” denote d-C 8 -alkylamino and di(d-C 8 -alkyl)amino, respectively, as hereinbefore defined, attached by a nitrogen atom to the carbon atom of a carbonyl group.
• d-C ⁇ -alkylaminocarbonyl and di(C 1 -C 8 -alkyl)-aminocarbonyl are, respectively, d-d-alkylaminocarbonyl and di(d-d-alkyl)-aminocarbonyl.
• 4- to 10-membered heterocyclic group containing at least one ring heteroatom selected from the group consisting of nitrogen, oxygen and sulphur may be moncyclic or bicyclic, e.g., furan, tetrahydrofuran, pyrrole, pyrrolidine, pyrazole, imidazole, triazole, isotriazole, tetrazole, thiadiazole, isothiazole, oxadiazole, pyridine, oxazole, isoxazole, pyrazine, pyridazine, pyrimidine, piperidine, piperazine, morpholine, triazine, oxazine, thiazole, quinoline, isoquinoline, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzofuran, indole, indazole or benzimidazo
• Preferred heterocyclic groups include piperazine, morpholine, imidazole, isotriazole, pyrazole, pyridine, furan, oxazole, oxadiazole, isoxazole, thiazole, tetrazole benzothiophene, benzoxazole, benzothiazole and benzofuran.
• the 4- to 10-membered heterocyclic group can be unsubstituted or substituted.
• Preferred substituents include halo, cyano, oxo, hydroxy, carboxy, nitro, d-C 8 -alkyl, d-C 8 -alkylcarbonyl, hydroxy-d-C 8 -alkyl, d-C 8 -haloalkyl, amino- d-C 8 -alkyl, amino(hydroxy)d-C 8 -alkyl and d-C 8 -alkoxy optionally substituted by aminocarbonyl.
• substituents include halo, oxo, d-d-alkyl, d-d-alkylcarbonyl, hydroxy-d-C 4 -alkyl, d-d-haloalkyl, amino-d-C 4 -alkyl and amino(hydroxy)d-C 4 -alkyl.
• compositions represented by formula (I) are capable of forming acid addition salts, particularly pharmaceutically acceptable acid addition salts.
• Pharmaceutically acceptable acid addition salts of the compound of formula (I) include those of inorganic acids, e.g., hydrohalic acids, such as hydrochloric acid or hydrobromic acid; nitric acid; sulphuric acid; phosphoric acid; and organic acids, e.g., aliphatic monocarboxyiic acids, such as formic acid, acetic acid, diphenylacetic acid, triphenylacetic acid, caprylic acid, dichloroacetic acid, trifluoroacetic acid, hippuric acid, propionic acid and butyric acid; aliphatic hydroxy acids, such as lactic acid, citric acid, gluconic acid, mandelic acid, tartaric acid or malic acid; dicarboxylic acids, such as adipic acid, aspartic acid, fumaric acid, glutamic acid, maleic acid, malonic acid, sebac
• Compounds of formula (I) which contain acidic, e.g., carboxyl, groups, are also capable of forming salts with bases, in particular, pharmaceutically acceptable bases, such as those well-known in the art; suitable such salts include metal salts, particularly, alkali metal or alkaline earth metal salts, such as sodium, potassium, magnesium, calcium or zinc salts; or salts with ammonia or pharmaceutically acceptable organic amines or heterocyclic bases, such as benethamine, benzathine, diethanolamine, ethanolamine, 4-(2-hydroxyethyl)morpholine,1-(2-hydroxyethyl)pyrrolidine, ⁇ /-methyl glucamine, piperazine, triethanolamine or tromethamine.
• These salts may be prepared from compounds of formula (I) by known salt-forming procedures.
• the compounds exist in individual optically active isomeric forms or as mixtures thereof, e.g., as racemic or diastereomeric mixtures.
• the present invention embraces both individual optically active R and S isomers, as well as mixtures, e.g., racemic or diastereomeric mixtures thereof.
• prodrugs are known to enhance numerous desirable qualities of pharmaceuticals, e.g., solubility, bioavailability, manufacturing, etc.
• the compounds of the present invention may be delivered in prodrug form.
• the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same.
• Prodrugs are intended to include any covalently bonded carriers which release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject.
• Prodrugs of the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
• Prodrugs include compounds of the present invention wherein a hydroxy, amino or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino or free sulfhydryl group, respectively.
• Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention.
• “Therapeutically effective amount” is intended to include an amount of a compound of the present invention alone or an amount of the combination of compounds claimed or an amount of a compound of the present invention in combination with other active ingredients effective to treat the inflammatory diseases described herein.
• treating cover the treatment of a disease-state in a mammal, particularly in a human, and include:
• R 1 is R 13 S-, R 1a O- or R 13 NR 9 , where R 1a is ° ; and all other symbols are as hereinbefore defined, cleaving an ester group -COOR 10 in a compound of formula (I), wherein
• R 1 is R 13 S-, R 13 O- or R 13 NR 9 , where
• R 10 is selected from C 1 -C 8 alkyl, C 3 -C 15 -cycloalkyl, Ci-C 8 -alkyl(C 6 -C 15 -aromatic carbocyclic group) and C 6 -C 15 -aromatic carboxylic group; and all other symbols are as hereinbefore defined;
• R 1 is OH
• Q is -COOR 6 ;
• R 1 is OH;
• R 6 is d-Cs-alkyl, C 3 -C 5 -cycloalkyl, Ci-C 8 -alkyl(C 6 -Ci 5 -aromatic carbocyclic group), or C 6 -Ci 5 -aromatic carboxylic group; and all other symbols are as hereinbefore defined; or
• Q is -COOR 6 or -C(O)NR 7 R 8 ;
• R 6 is d-Cs-alkyl, C 3 -C 5 -cycloalkyl, carbocyclic group), and C 6 -C 15 -aromatic carboxylic group;
• R 7 and R 8 are, as hereinbefore defined, appropriately esterifying or amidifying a compound of formula (I), where Q is -COOH;
• Process variants (A), (B) and (C) may be carried out using known procedures for ester cleavage or analogously as hereinafter described in the Examples.
• Process variant (C) may be carried out using known procedures for conversion of a carboxylic acid to an ester or amide of the acid or analogously, as hereinafter described in the Examples.
• Starting materials for process variants (A)-(C) 1 and compounds for the preparation of those starting materials may be novel or known; they may be prepared in accordance with known procedures or analogously, as hereinafter described in the Examples.
• Another embodiment of the present invention provides compounds of formula (III)
• R 2 and R 3 are, independently, H, d-C 8 -aIkyl or together with the carbon atom to which they are attached form a divalent C 3 -C 8 -cycloaliphatic group;
• R 4 and R 5 are, independently, halogen, d-C ⁇ -alkyl, d-C 8 -haloalkyl, a C 3 -C 15 -carbocyclic group, nitro, cyano, d-C 8 -alkylsulfonyl, d-C 8 -alkylcarbonyl, d-C 8 -alkoxycarbonyl, d-C 8 -alkoxy, d-C 8 -haloalkoxy, carboxy, carboxy-d-C 8 -alkyl, amino, Ci-C 8 -alkylamino, di(d-C 8 -alkyl)amino, SO 2 NH 2 , di(d-C 8 -alkyl)aminosulfonyl, aminocarbonyl, d-C ⁇ -alkylaminocarbonyl, di(d-C 8 - alkyl)aminocarbonyl or a 4- to 10-membered heterocyclic group having
• R 6 is selected from H, d-C 8 -alkyl, C 3 -C 5 -cycloalkyl, d-C 8 -alkyl(C 6 -C 15 -aromatic carbocyclic group) and C 6 -d 5 -aromatic carbocyclic group;
• X is -CH 2 -, -CO-, -CH(OH)-, -CH(Od-C 8 -alkyl)-, -C(halogen) 2 -,-O-, -S-, -SO- or -SO 2 -;
• Y is -O-, -S-, -CH 2 - or -NR 11 (Ci-C 8 -alkyl);
• R 11 is selected from H, Ci-C 8 -alkyl, C 3 -C 15 -cycloalkyl, d-C 8 -alkyl(C 6 -Ci 5 -aromatic carbocyclic group) and C 6 -Ci 5 -aromatic carbocyclic group;
• R 14 is -(CR 1b R 1c ) p CN, wherein R 1b and R 1c are, independently, H or d-C 8 -alkyl; m and n are each, independently, an integer selected from 0-3; p is an integer selected from 0-2; and w is an integer selected from 0-3.
• R 6 is d-C ⁇ -alkyl, may be prepared by reacting a compound of formula (IV) with a corresponding haloalkyl nitrile, wherein
• R 6 is d-C ⁇ -alkyl
• R 12 and R 13 are, independently, H 1 halogen, d-C ⁇ -alkyl, d-C 8 -haloalkyl, a C 3 -Ci 5 -carbocyclic group, nitro, cyano, d-C 8 -alkylsulfinyl, d-C ⁇ -alkylsulfonyl, d-C 8 -haloalkylsulfonyl d-C 8 -alkylcarbonyl, CrC ⁇ -alkoxycarbonyl, d-C 8 -alkoxy, d-C 8 -haloalkoxy, carboxy, carboxy- d-C 8 -alkyl, amino, d-C 8 -alkylamino, di(C 1 -C 8 -alkyl)amino, SO 2 NH 2 , (d-C ⁇ -alkylaminoJsulfonyl, di(C 1 -C 8 -alkyl)ami
• the compounds of formula (I) can be prepared, e.g., using the reactions and techniques described below.
• the reactions may be performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention.
• the various substituents on the synthetic intermediates and final products shown in the following reaction schemes can be present in their fully elaborated forms, with suitable protecting groups where required as understood by one skilled in the art, or in precursor forms which can later be elaborated into their final forms by methods familiar to one skilled in the art.
• the substituents can also be added at various stages throughout the synthetic sequence or after completion of the synthetic sequence.
• commonly used functional group manipulations can be used to transform one intermediate into another intermediate, or one compound of formula (I) into another compound of formula (I). Examples of such manipulations are conversion of an ester or a ketone to an alcohol; conversion of an ester to a ketone; interconversions of esters, acids and amides; alkylation, acylation and sulfonylation of alcohols and amines; and many others.
• Substituents can also be added using common reactions, such as alkylation, acylation, halogenation or oxidation. Such manipulations are well-known in the art, and many reference works summarize procedures and methods for such manipulations.
• Scheme 2 also demonstrates another method for the preparation of compounds of formula (I). This method involves the cross-coupling of a benzyl halide, i.e., a benzyl bromide 6 with an aromatic boronic acid 7 and a palladium catalyst to generate intermediate 8. De-methylation of 8 and subsequent /?/s-alkylation with a haloacetate and hydrolysis yields compound 9.
• phenols such as 2 (Scheme 1) are treated with acetone and chloroform in the presence of an inorganic base, such as NaOH as in J Med Chem, Vol. 32, pp. 2460-2467 (1989).
• diesters such as 3 (Scheme 1) are treated with chromium trioxide in the presence of a carboxylic acid, such as acetic acid as in J Org Chem, Vol. 8, pp. 316-319 (1943), followed by ester hydrolysis.
• a carboxylic acid such as acetic acid
• LCMS are recorded on an Agilent 1100 LC system with a Waters Xterra MS C18 4.6 x 100 5 ⁇ M column, eluting with 5-95% 10 mM aqueous ammonium bicarbonate in acetonitrile over 2.5 minutes, with negative ion electrospray ionization or 5-95% water + 0.1% TFA in acetonitrile with positive ion electrospray ionization.
• Cesium carbonate 60 g, 184 mmol is added portionwise to a cooled (O 0 C) solution of 2,2'-methylene-6/s(4-chlorophenol) (24.48 g, 91 mmol) in DMF (120 mL), followed by methyl bromoacetate (17.3 mL, 184 mmol).
• the reaction is stirred at ambient temperature for 16 hours, then poured into 1 M aqueous HCI (1 ,000 mL) with ice bath cooling.
• reaction is stirred at -15°C to -10°C for 2 hours, prior to sequential addition of aminocyclopropane (90 ⁇ L, 0.13 mmol) and DMAP (31 mg, 0.26 mmol). After a further 1.5 hours, the reaction mixture is warmed to ambient temperature and the solvent is evaporated. The residue is taken into EtOAc containing 10% MeOH, washed with 1 M aqueous HCI followed by brine, dried Na 2 SO 4 and evaporated.
• Phosphorus tribromide (0.312 mL, 3.28 mmol) is added to a solution of (5-fluoro-2- methoxy-phenyl)-methanol (1.03 g, 6.56 mmol) in DCM (10 mL). After 30 minutes, the reaction mixture is poured directly on to a silica gel column and eluted with DCM to afford 2-bromomethyl-4-fluoro-1-methoxy-benzene.
• 2,2'-Methylene- ⁇ b/s(4-chloro-phenol) (12 g, 44.6 mmol) is dissolved in DMF (100 mL). Lithium carbonate (3.3 g, 44.6 mmol) was added, followed by benzyl-2-bromoacetate (7.7 mL, 49 mmol). The suspension is stirred at 80 0 C for 8 hours. Further benzyl-2- bromoacetate (1 mL, 6.4 mmol) is added and stirring continued at 100°C for 4 hours. The reaction mixture is evaporated to dryness, water is added to the residue which is acidified to pH 1 with 2 M aqueous HCI and extracted with EtOAc.
• 2,2'-Methylene-6/s(4-chloro-phenol) (12 g, 44.6 mmol) is dissolved in DMF (100 ml_). Lithium carbonate (3.3 g, 44.6 mmol) was added, followed by benzyl-2-bromoacetate (7.7 ml_, 49 mmol). The suspension is stirred at 80 0 C for 8 hours. Further benzyl-2- bromoacetate (1 ml_, 6.4 mmol) is added and stirring continued at 100°C for 4 hours. The reaction mixture is evaporated to dryness, water is added to the residue which is acidified to pH 1 with 2 M aqueous HCI and extracted with EtOAc.
• MH + refers to monoisotopic molecular weights
• compositions of formulae (I) and (Ia) and their pharmaceutically acceptable salts are useful as pharmaceuticals.
• the compounds have good CRTh 2 receptor antagonist activity and may be tested in the following assays.
• Membranes are prepared from K562 or Chinese Hamster Ovary (CHO) cells stably transfected with human CRTh 2 receptors.
• the assay is performed in a 96-well U-bottomed polypropylene plate in a final volume of 100 ⁇ l_ and the components of the assay are added as follows: test compound in DMSO/assay buffer (25 ⁇ l_), 3 H prostaglandin D 2 (PGD 2 ) (25 ⁇ L) and CRTh 2 membrane fragments (50 ⁇ L).
• the assay is incubated at ambient temperature with shaking for 60 minutes, then harvested on to filter plates.
• the plate is dried for 2 hours, prior to addition of Micro-Scint 20TM (50 ⁇ L) and sealing with TopSeal-STM. Plates are then counted using a Packard Top Count instrument, each well being counted for 20 minutes. Ki values are determined using Sigma PlotTM software.
• Test compounds are prepared in assay stimulation buffer/DMSO and 5 ⁇ L/well is added to an assay plate (384-well white opti-plate).
• CHO cells stably transfected with the CRTh 2 receptor are prepared (dissociated from a cell culture flask and washed in PBS) to a concentration of 4 x 10 6 AnL in assay stimulation buffer and added to the assay plate (10 ⁇ L/well).
• the assay plate is incubated at room temperature on a shaker for 15 minutes.
• a mix of agonist (10 nM PGD 2 ) and 5 ⁇ M forskolin is prepared in assay stimulation buffer and added to the assay plate (5 ⁇ L/well).
• a cAMP standard is serially diluted in assay stimulation buffer and added to separate empty wells on the assay plate (20 ⁇ L/well).
• the assay plate is incubated at room temperature on a shaker for 60 minutes.
• a cell lysis mix (lysis buffer containing AlphascreenTM donor beads and biotinylated cAMP) is prepared under darkened conditions 60 minutes prior to addition. AlphascreenTM acceptor beads are added to the lysis mix after 60 minutes. The resulting lysis mix is added to all wells of the assay plate (40 ⁇ L/well).
• the assay plate is sealed with Topseal-STM and incubated in the dark at room temperature on a shaker for 45 minutes. The plate is then counted using a Packard FusionTM instrument.
• IC 50 values are then determined using PrismTM software.
• Ki values in the SPA binding assay below 1 ⁇ M The compounds also generally have IC 50 values in the functional assays below 1 ⁇ M.
• Compounds of the Examples, herein below generally have Ki values in the SPA binding assay below 1 ⁇ M.
• the compounds of Examples 2 and 13 have Ki values of 0.0.008 and 0.058 ⁇ M, respectively.
• Compounds of the Examples, herein below generally have IC 50 values in the functional assay below 1 ⁇ M.
• the compounds of Examples 2, and 13 have IC 50 values of 0.068 and 0.052 ⁇ M, respectively.
• Compounds of formulae (I) and (Ia), in free or salt form, are antagonists of the G-protein-coupled chemoattractant receptor CRTh 2 , expressed on Th 2 cells, eosinophils and basophils.
• PGD 2 is the natural ligand for CRTh 2 .
• antagonists which inhibit the binding of CRTh 2 and PGD 2 are useful in the treatment of allergic and anti-inflammatory conditions. Treatment in accordance with the invention may be symptomatic or prophylactic.
• agents of the invention are useful in the treatment of inflammatory or obstructive airways diseases, resulting, e.g., in reduction of tissue damage, airways inflammation, bronchial hyperreactivity, remodeling or disease progression.
• Inflammatory or obstructive airways diseases to which the present invention is applicable include asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitis asthma, exercise-induced asthma, occupational asthma and asthma induced following bacterial infection.
• Treatment of asthma is also to be understood as embracing treatment of subjects, e.g., of less than 4 or 5 years of age, exhibiting wheezing symptoms and diagnosed or diagnosable as "whez infants", an established patient category of major medical concern and now often identified as incipient or early-phase asthmatics. (For convenience this particular asthmatic condition is referred to as "whez-infant syndrome”.)
• Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g., of acute asthmatic or bronchoconstrictor attack, improvement in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, i.e., therapy for or intended to restrict or abort symptomatic attack when it occurs, e.g., anti-inflammatory (e.g., corticosteroid) or bronchodilatory. Prophylactic benefit in asthma may, in particular, be apparent in subjects prone to "morning dipping".
• “Morning dipping” is a recognized asthmatic syndrome, common to a substantial percentage of asthmatics and characterized by asthma attack, e.g., between the hours of about 4-6 a.m., i.e., at a time normally substantially distant from any previously administered symptomatic asthma therapy.
• Other inflammatory or obstructive airways diseases and conditions to which the present invention is applicable include acute lung injury (ALI), adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD, COAD or COLD), including chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular, other inhaled drug therapy.
• ALI acute lung injury
• ARDS adult respiratory distress syndrome
• COAD or COLD chronic obstructive pulmonary, airways or lung disease
• chronic bronchitis or dyspnea associated therewith emphysema
• the invention is also applicable to the treatment of bronchitis of whatever type or genesis including, e.g., acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis.
• inflammatory or obstructive airways diseases to which the present invention is applicable include pneumoconiosis (an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts) of whatever type or genesis including, e.g., aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis.
• agents of the invention are also useful in the treatment of eosinophil related disorders, e.g., eosinophilia, in particular, eosinophils-related disorders of the airways, e.g., involving morbid eosinophilic infiltration of pulmonary tissues including hypereosinophilia as it effects the airways and/or lungs, as well as, e.g., eosinophil-related disorders of the airways consequential or concomitant to L ⁇ ffler's syndrome; eosinophilic pneumonia; parasitic, in particular, metazoan, infestation including tropical eosinophilia; bronchopulmonary aspergillosis; polyarteritis nodosa including Churg-Strauss syndrome; eosinophilic granuloma; and eosinophil-related disorders affecting the airways occasione
• eosinophil related disorders e.g., eosinophilia, in
• Agents of the invention are also useful in the treatment of inflammatory or allergic conditions of the skin, e.g., psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis bullosa acquisita and other inflammatory or allergic conditions of the skin.
• Agents of the invention may also be used for the treatment of other diseases or conditions, in particular, diseases or conditions having an inflammatory component, e.g., treatment of diseases and conditions of the eye, such as conjunctivitis, keratoconjunctivitis sicca and vernal conjunctivitis; diseases affecting the nose including allergic rhinitis; and inflammatory disease, in which autoimmune reactions are implicated or having an autoimmune component or aetiology, including autoimmune hematological disorders, e.g., hemolytic anemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia; systemic lupus erythematosus; polychondritis; sclerodoma; Wegener granulamatosis; dermatomyositis; chronic active hepatitis; myasthenia gravis; Steven-Johnson syndrome; idiopathic sprue; autoimmune inflammatory bowel disease, e.
• diseases or conditions which may be treated with agents of the invention include septic shock; rheumatoid arthritis; osteoarthritis; proliferative diseases, such as cancer; atherosclerosis; allograft rejection following transplantation; stroke; obesity; restenosis; diabetes, e.g., diabetes mellitus type I (juvenile diabetes) and diabetes mellitus type II; diarrheal diseases; ischemia/reperfusion injuries; retinopathy, such as diabetic retinopathy or hyperbaric oxygen-induced retinopathy; and conditions characterized by elevated intraocular pressure or secretion of ocular aqueous humor, such as glaucoma.
• an agent of the invention in inhibiting inflammatory conditions, e.g., in inflammatory airways diseases, may be demonstrated in an animal model, e.g., a mouse or rat model, of airways inflammation or other inflammatory conditions, e.g., as described by Szarka et al., J Immunol Methods, Vol. 202, pp. 49-57 (1997); Renzi et al., Am Rev Respir Dis, Vol. 148, pp. 932-939 (1993); Tsuyuki et al., J Clin Invest, Vol. 96, pp. 2924-2931 (1995); Cernadas et al., Am J Respir Cell MoI Biol, Vol. 20, pp. 1-8 (1999); and Williams and GaIIi, J Exp Med, Vol. 192, pp. 455-462 (2000).
• the agents of the invention are also useful as co-therapeutic agents for use in combination with other drug substances, such as anti-inflammatory, bronchodilatory or antihistamine drug substances, particularly in the treatment of obstructive or inflammatory airways diseases, such as those mentioned hereinbefore, e.g., as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs.
• An agent of the invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance.
• the invention includes a combination of an agent of the invention as hereinbefore described with an anti-inflammatory, bronchodilatory, antihistamine or anti-tussive drug substance, said agent of the invention and said drug substance being in the same or different pharmaceutical composition.
• Such anti-inflammatory drugs include steroids, in particular, glucocorticosteroids, such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate; or steroids, described in WO 02/88167, WO 02/12266, WO 02/100879, WO 02/00679 (especially those of Examples 3, 11 , 14, 17, 19, 26, 34, 37, 39, 51 , 60, 67, 72, 73, 90, 99 and 101), WO 03/035668, WO 03/048181, WO 03/062259, WO 03/064445 and WO 03/072592, WO 04/039827, WO 04/066920; non-steroidal glucocorticoid receptor agonists, such as those described in WO 00/00531 , WO 02/10143, DE 10261874, WO 03/082280, WO 03/082787, WO 03/104195
• ⁇ -2-adrenoreceptor agonists include compounds of JP 05025045, WO 93/18007, WO 99/64035, U.S. Patent No.
• Such bronchodilatory drugs include anticholinergic or antimuscarinic agents, in particular, ipratropium bromide, oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), but also those described in WO 01/04118, WO 02/51841 , WO 02/53564, WO 03/00840, WO 03/87094, WO 04/05285, WO 02/00652, WO 03/53966, EP 0424021 , U.S. Patent No. 5,171 ,744, U.S. Patent No. 3,714,357 and WO 03/33495.
• anticholinergic or antimuscarinic agents in particular, ipratropium bromide, oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), but also those described in WO 01/04118, WO 02/51841 , WO 02/53564, WO 03/00840, WO 03/87094, WO 04
• Such co-therapeutic antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride.
• Combinations of agents of the invention and steroids, ⁇ -2 agonists, PDE4 inhibitors or LTD4 antagonists may be used, e.g., in the treatment of COPD or, particularly, asthma.
• Combinations of agents of the invention and anticholinergic or antimuscarinic agents, PDE4 inhibitors, dopamine receptor agonists or LTB4 antagonists may be used, e.g., in the treatment of asthma or, particularly, COPD.
• agents of the invention with anti-inflammatory drugs are those with antagonists of chemokine receptors, e.g., CCR-1 , CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9, CCR-10, CXCR1 , CXCR2, CXCR3, CXCR4 and CXCR5; particularly useful are CCR-3 antagonists, such as those described in WO 02/026723, especially 4- ⁇ 3-[(S)-4-(3,4-dichlorobenzyl)-morpholin-2-ylmethyl]-ureidomethyl ⁇ -benzamide and those described in WO 03/077907, WO 03/007939 and WO 02/102775.
• CCR-3 antagonists such as those described in WO 02/026723, especially 4- ⁇ 3-[(S)-4-(3,4-dichlorobenzyl)-morpholin-2-ylmethyl]-ureidomethyl ⁇ -benzamide and those described in WO 03/
• CCR-5 antagonists such as Schering-Plough antagonists SC-351125, SCH-55700 and SCH-D; Takeda antagonists, such as ⁇ /-[[4-[[[6,7-dihydro-2-(4- methylphenyl)-5/-/-benzo-cyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro- ⁇ /, ⁇ /- dimethyl-2H-pyran-4-aminium chloride (TAK-770); and CCR-5 antagonists, described in U.S. Patent No. 6,166,037, WO 00/66558 and WO 00/66559.
• TAK-770 dimethyl-2H-pyran-4-aminium chloride
• the agents of the invention may be administered by any appropriate route, e.g., orally, e.g., in the form of a tablet or capsule; parenterally, e.g., intravenously; by inhalation, e.g., in the treatment of inflammatory or obstructive airways disease; intranasally, e.g., in the treatment of allergic rhinitis; topically to the skin, e.g., in the treatment of atopic dermatitis; or rectally, e.g., in the treatment of inflammatory bowel disease.
• routes e.g., orally, e.g., in the form of a tablet or capsule; parenterally, e.g., intravenously; by inhalation, e.g., in the treatment of inflammatory or obstructive airways disease; intranasally, e.g., in the treatment of allergic rhinitis; topically to the skin, e.g., in the treatment
• the present invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising a compound of formula (I), in free form or in the form of a pharmaceutically acceptable salt, optionally together with a pharmaceutically acceptable diluent or carrier therefore.
• the composition may contain a co-therapeutic agent, such as an anti-inflammatory, bronchodilatory or antihistamine drug, as hereinbefore described.
• Such compositions may be prepared using conventional diluents or excipients and techniques known in the galenic art.
• oral dosage forms may include tablets and capsules.
• Formulations for topical administration may take the form of creams, ointments, gels or transdermal delivery systems, e.g., patches.
• Compositions for inhalation may comprise aerosol or other atomizable formulations or dry powder formulations.
• the present invention also provides for the use of a compound of the present invention in any of the aforementioned embodiments, in free or pharmaceutically acceptable salt form, for the manufacture of a medicament for the treatment of an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease.
• the present invention also provides a method for treating or preventing inflammatory or allergic conditions comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, in free or a pharmaceutically acceptable salt form.
• a pharmaceutically acceptable salt form e.g., a hydro-fluoro-alkane (HFA) propellant, such as HFA134a or HFA227 or a mixture of these, and may contain one or more co-solvents known in the art, such as ethanol (up to 20% by weight); and/or one or more surfactants, such as oleic acid or sorbitan trioleate; and/or one or more bulking agents, such as lactose.
• HFA hydro-fluoro-alkane
• the composition comprises a dry powder formulation, it preferably contains, e.g., the compound of formula (I) having a particle diameter up to 10 microns, optionally together with a diluent or carrier, such as lactose, of the desired particle size distribution and a compound that helps to protect against product performance deterioration due to moisture.
• a diluent or carrier such as lactose
• the composition comprises a nebulized formulation, it preferably contains, e.g., the compound of formula (I), either dissolved or suspended, in a vehicle containing water, a co-solvent, such as ethanol or propylene glycol and a stabilizer, which may be a surfactant.
• the invention includes:
• an agent of the invention in inhalable form e.g., in an aerosol or other atomizable composition or in inhalable particulate, e.g., micronized form;
• Dosages of agents of the invention employed in practicing the present invention will of course vary depending, e.g., on the particular condition to be treated, the effect desired and the mode of administration. In general, suitable daily dosages for oral administration are of the order of 0.01-100 mg/kg.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pulmonology (AREA)
• Immunology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34834562

Family Applications (1)

Country Status (12)

Cited By (6)

Citations (6)

Family Cites Families (1)

• 2005
  • 2005-05-24 GB GBGB0510585.3A patent/GB0510585D0/en not_active Ceased
• 2006
  • 2006-05-22 AU AU2006251393A patent/AU2006251393A1/en not_active Abandoned
  • 2006-05-22 MX MX2007014785A patent/MX2007014785A/es not_active Application Discontinuation
  • 2006-05-22 JP JP2008512750A patent/JP2008545672A/ja active Pending
  • 2006-05-22 RU RU2007147429/04A patent/RU2007147429A/ru not_active Application Discontinuation
  • 2006-05-22 BR BRPI0610303-0A patent/BRPI0610303A2/pt not_active IP Right Cessation
  • 2006-05-22 CA CA002608678A patent/CA2608678A1/en not_active Abandoned
  • 2006-05-22 CN CNA2006800179674A patent/CN101180260A/zh active Pending
  • 2006-05-22 KR KR1020077027360A patent/KR20080009214A/ko not_active Withdrawn
  • 2006-05-22 EP EP06753777A patent/EP1888505A1/en not_active Withdrawn
  • 2006-05-22 WO PCT/EP2006/004844 patent/WO2006125593A1/en not_active Ceased
  • 2006-05-22 US US11/915,091 patent/US20080312322A1/en not_active Abandoned

Patent Citations (6)

Non-Patent Citations (25)

Also Published As

Similar Documents

Legal Events